Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

Core Insights - Moffitt Cancer Center and Cryoport, Inc. have announced a strategic collaboration to provide state-of-the-art biorepository services through Cryoport's CRYOGENE unit, enhancing Moffitt's capabilities in cell and gene therapies [1][2][3] Company Overview - Moffitt Cancer Center is a National Cancer Institute-designated comprehensive cancer center focused on cancer prevention and treatment, recognized for its scientific excellence and multidisciplinary research [9] - Cryoport, Inc. is a global leader in supply chain solutions for the life sciences industry, specializing in biostorage and logistics services for cell and gene therapies [10][11] Collaboration Details - The collaboration aims to transform Moffitt's Speros campus into a global epicenter for innovation in various therapies, including cell and gene therapies, immunotherapies, and radiopharmaceuticals [2][3][4] - CRYOGENE will provide advanced biostorage technologies and logistics services, supporting both patient treatments and medical research at Moffitt [3][4] Market Potential - The cell and gene therapy industry is projected to exceed $97 billion by 2033, with a compound annual growth rate of 18.3% from 2024 to 2033, highlighting the growing demand for biorepository services [3] Infrastructure Development - The CRYOGENE facility will be integrated into the initial phase of the Speros campus development, located next to Moffitt's Discovery & Innovation Center, which spans 250,000 square feet [2][4] - Speros aims to create a comprehensive ecosystem for life sciences, focusing on critical activities such as drug discovery, artificial intelligence, and biotech [5][6]